VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

MonoSol Rx, Inc. company develops thin film versions (about the size of a postage stamp) of new and existing prescription and over-the-counter drugs for colds, nausea, pain, and other ailments. MonoSol creates its thin film products, which are easier to take than tablets or capsules, primarily through partnerships with other pharmaceutical companies. Brands of current drug candidates for its thin film strips include Ambien, a sleep aid, and Lexapro, an anti-depressant. The company has a manufacturing facility in Portage, Indiana, and focuses on creating products for US, Europe, and Asia/Pacific markets.

Cyclacel Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Quick-Med Technologies, Inc. was founded in 1997 and is headquartered in Gainesville, Florida. Quick-Med Technologies, Inc., a life sciences company, develops technologies for the medical and consumer healthcare markets in the United States. Quick-Med Technologies's technologies under development include NIMBUS, a family of organic molecules or polymers that are bio-engineered to have antimicrobial, hemostatic, and other properties, which could be used in a range of medical device applications, including contact lenses, wound dressings, incontinence products, or disposable gloves; and Stay Fresh, a chemical formulation for textiles that provides a durable antimicrobial agent, which can be bonded to fibers or fabrics so as to retain the biocidal property through various launderings and is suitable for a range of applications, including apparel, sportswear, active wear, and work wear, as well as furnishings, such as linens, drapes, and towels. Its other technologies under development comprise NimbuDerm, a novel copolymer used as a persistent hand sanitizer; and MultiStat, a family of matrix metalloproteinase inhibitors that are used for the maintenance, healing, and repair of skin and eyes.

ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California. ISTA Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company with products and product candidates for the treatment of inflammation, ocular pain, glaucoma, allergy and dry eye. The Company has three products available for sale in the United States: Xibrom, (bromfenac ophthalmic solution) for the treatment of inflammation and pain following cataract surgery, Istalol, (timolol maleate ophthalmic solution) for the treatment of glaucoma, and Vitrase (hyaluronidase for injection) for use as a spreading agent. The Company also has several product candidates in various stages of development. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma.

Marligen Biosciences is where researchers go again and again for testing products and services. The company makes nucleic acid purification systems, genetic analysis assays, and other genomics research supplies. Its nucleic acid purification systems include rapid plasma purification systems which are used for isolation DNA so it can mapped, cloned, amplified, labeled, and sequenced. Its genetic analysis assays are sold under the Signet brand name and can screen for certain classes of DNA or be tailored to the researchers needs. Marlingen was acquired by another genetic services provider, OriGene, in 2009.

Stellar Pharmaceuticals Inc. company was founded in 1978 and is based in London, Canada. Stellar Pharmaceuticals Inc. engages in the development and marketing of polysaccharide-based therapeutic products used in the treatment of osteoarthritis and cystitis. It offers NeoVisc, a three injection sodium hyaluronate therapy for the treatment of osteoarthritis; and Uracyst for the treatment of interstitial cystitis, a painful bladder syndrome an inflammatory disease of the urinary bladder wall. The company also has in-licensing agreement for the distribution and sale of BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. Stellar markets its products to medical physicians, pharmacies, hospitals, and patient support groups in Canada through its sales force, as well as out-licenses its products to companies in the United States, Europe, Romania, the Russian Federation, China, Israel, the Middle East, Latin America, the Caribbean, Malaysia, Singapore, and Brunei.

BBI Holdings Plc, through its subsidiaries, engages in the development and manufacture of noninvasive lateral flow tests, and the distribution of diabetes products in the United Kingdom and internationally. It operates in three divisions: Diagnostics, Enzymes, and Healthcare. The Diagnostics division involves in the development, manufacture, supply of reagents. The Enzymes engages in the manufacturer and supply of specialist natural enzymes to the medical diagnostics industry. The Healthcare segment involves in the sale and marketing of GlucoGel, a dextrose gel used by diabetes patients when they experience hypoglycaemia; and development of diabetes care product portfolio. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom. As of February 12, 2008, BBI Holdings plc operates as a subsidiary of Inverness Medical Innovations Inc.

Sino Biopharmaceutical manufactures medicines that combat cardio-cerebral diseases and hepatitis. Incorporated in 2000, Sino markets its products throughout China in the form of volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines, and granulated medicines. It is additionally researching and developing new medicines in the realms of oncology, analgesic, and respiratory treatment. Sino primarily operates through four main subsidiaries: Beijing Tide Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Beijing Chia Tai Green Continent Pharmaceutical.

Herborium Group is a developer and marketer of herbal nutritional supplements. Herborium's product line includes Traditional Chinese Medicine herbal blends designed to clear up acne (AcnEase), boost energy (Energy Restoration), and heighten sexual performance (Lasting Pleasure for women, MaleForce for men). Herborium sells it products in the US, the UK, and continental Europe through a network of distributors, specialty retailers, such as natural foods stores, and online marketplaces. The company's founder, president and CEO Agnes Olszewski and director James Gilligan hold about 70% of the company's shares.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.